| HOME >> MEDICINE >> TECHNOLOGY |
1,138999Total current liabilities
27,61222,044Long-term debt
1,7022,573Deferred revenue
2,9333,344Other
5,0853,831Total liabilities
37,33231,792Stockholders' equity:Common stock
4141Additional paid-in capital
293,392297,104Accumulated other comprehensive gain
1,101984Accumulated deficit
(34,867)(47,274)Total stockholders' equity
259,667250,855Total liabilities and stockholders' equity
$
296,999$
282,647
LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2012201120122011(unaudited)(unaudited)Revenue
$ 55,535$ 47,869$ 202,582$ 184,339Cost of revenue
16,17815,35060,00858,849Gross profit
39,35732,519142,574125,490Operating expenses:Research and development
10,9909,88240,77533,394Selling, general and administrative
20,08317,61074,84064,878Amortization of acquired intangible assets
1,0291,0954,2433,375Total operating expenses
32,10228,587119,858101,647Income from operations
7,2553,93222,71623,843Interest expense from long-term debt
(36)(73)(198)(308)Other income, net
138107262394Income before income taxes
7,3573,96622,78023,929Income taxes
(3,105)(524)(10,373)(9,455)Net income
$ 4,252$ 3,442$
2,407$ 14,474Net income per share, basic
$
.10$
.08$
.30$
.35Shares used in computing net income per share, basic
40,72441,15340,92741,262Net income per share, diluted
$
.10$
.08$
.30$
.34Shares used in computing net income per share, diluted
41,33242,37641,88442,537
LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands
'/>"/>
| SOURCE Luminex Corporation Copyright©2012 PR Newswire. All rights reserved |